Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-136120

Published: 2020

Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Blood (2019) 134 (Supplement_1): 185.

https://doi.org/10.1182/blood-2019-131390

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Justin D. Kaner, MD, Montreh Tavakkoli, MA,MD, Lisa Toudic, Brett M. Stevens, PhD, Craig T Jordan, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Ellen K. Ritchie, MD, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Sangmin Lee, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 3935.

https://doi.org/10.1182/blood-2019-128276

Published: 2019

Journal Articles

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

Marlie H Fisher, Greg Kirkpatrick, PhD, Courtney L Jones, PhD, Brett M. Stevens, PhD, Michael Callaghan, MD, Eric Pietras, PhD, Kenneth L. Jones, PhD, Christopher C. Porter, MD, Jorge Di Paola, MD

Blood (2019) 134 (Supplement_1): 2316.

https://doi.org/10.1182/blood-2019-132032

Published: 2019

Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Blood (2019) 134 (Supplement_1): 2638.

https://doi.org/10.1182/blood-2019-122120

Published: 2019

Journal Articles

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

James Chavez, BS, Jennifer L Rabe, BS, BA, Kelly Higa, MS, Dirk Loeffler, Ahmed Nouraiz, PhD, Taylor Mills, BA, Beau M Idler, Brett M. Stevens, PhD, Courtney Fleenor, PhD, Claus Nerlov, PhD, Hideaki Nakajima, MD, James Hagman, Timm Schroeder, PhD, Hyun Min Kim, PhD, Craig T Jordan, PhD, James DeGregori, Eric Pietras, PhD

Blood (2019) 134 (Supplement_1): 822.

https://doi.org/10.1182/blood-2019-129300

Published: 2019

Journal Articles

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Courtney L Jones, PhD, Brett M. Stevens, PhD, Rachel Culp-Hill, BS, Angelo Dalessandro, PhD, Anna Krug, BS, Madeline Goosman, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2019) 134 (Supplement_1): 1272.

https://doi.org/10.1182/blood-2019-125773

Published: 2019

Journal Articles

Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism

Courtney L Jones, PhD, Brett M Stevens, PhD, Rachel Culp-Hill, BS, Travis Nemkov, Angelo D'Alessandro, PhD, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 429.

https://doi.org/10.1182/blood-2018-99-111366

Published: 2018

Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 432.

https://doi.org/10.1182/blood-2018-99-111507

Published: 2018

Journal Articles

Cysteine and Cystine Depletion Targets Leukemia Stem Cells

Courtney L Jones, PhD, Brett M Stevens, PhD, Angelo D'Alessandro, Rachel Culp-Hill, BS, Julie Reisz, PhD, Haobin Ye, PhD, Nabilah Khan, Mohd Minhajuddin, PhD, James DeGregori, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 431.

https://doi.org/10.1182/blood-2018-99-113181

Published: 2018

Journal Articles

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Brett M Stevens, PhD, Amanda Winters, MDPhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Ilu Kumari, M.Sc., Anuj Tyagi, M.Sc., Aftab Alam, M.Sc., Neelesh Lunkad, M.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD, Shireen Vali, PhD, Daniel A Pollyea, MD

Blood (2018) 132 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2018-99-114429

Published: 2018

Journal Articles

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Courtney L Jones, PhD, Brett M Stevens, PhD, Angelo D'Alessandro, PhD, Julia Reisz, PhD, Rachel Culp-Hill, BS, Travis Nemkov, Shanshan Pei, PhD, Nabilah Khan, Biniam Adane, PhD, Haobin Ye, PhD, Dominik Reinhold, Clayton Smith, MD, James DeGregori, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2018-99-111965

Published: 2018

Journal Articles

Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality

Blood (2018) 132 (Supplement 1): 2573.

https://doi.org/10.1182/blood-2018-99-120272

Published: 2018

Journal Articles

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Zachary J Walker, MS, Michael J VanWyngarden, BS, Brett M Stevens, PhD, Christophe Langouët-Astrie, MS, Clayton Smith, MD, Brent E Palmer, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Craig T Jordan, PhD, Daniel W Sherbenou, MD PhD

Blood (2018) 132 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2018-99-111394

Published: 2018

Journal Articles

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Amanda Winters, MD PhD, Madeline Goosman, Brett M Stevens, PhD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Daniel A Pollyea, MD, Craig T Jordan, PhD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2018-99-110834

Published: 2018

Journal Articles

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Brett M. Stevens, PhD, Amanda Winters, MD PhD, Jonathan A Gutman, MD, Aaron Fullerton, BS, Gregory Hemenway, MS2, Nicholas Miltgen, BS, Qi Wei, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Neeraj Kumar Singh, B.Tech, Leylah M. Drusbosky, PhD, Chris R. Cogle, MD, Andrew Hammes, MS, Craig T. Jordan, PhD, Daniel A. Pollyea, MD

Blood (2017) 130 (Supplement 1): 1337.

https://doi.org/10.1182/blood.V130.Suppl_1.1337.1337

Published: 2017

Journal Articles

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Daniel A. Pollyea, MD, Brett M. Stevens, PhD, Amanda Winters, MD PhD, Mohd Minhajuddin, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD FRCPC, Diana Abbott, PhD, Craig T. Jordan, PhD

Blood (2017) 130 (Supplement 1): 181.

https://doi.org/10.1182/blood.V130.Suppl_1.181.181

Published: 2017

Journal Articles

Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention

Brett M Stevens, PhD, Daniel A Pollyea, MD, Nabilah Khan, PhD, Craig T Jordan, PhD

Blood (2016) 128 (22): 4316.

https://doi.org/10.1182/blood.V128.22.4316.4316

Published: 2016

Journal Articles

The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis

Biniam Adane, BS, Haobin Ye, PhD, Shanshan Pei, PhD, Nabilah Khan, PhD, Mohammad Minhajuddin, PhD, Brett M Stevens, PhD, Vadym Zaberezhnyy, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2016) 128 (22): 1079.

https://doi.org/10.1182/blood.V128.22.1079.1079

Published: 2016

NARROW

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Cysteine and Cystine Depletion Targets Leukemia Stem Cells

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention

The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only